Tearscience announced that Joseph Boorady, OD, will take the helm as president and chief executive officer. Dr. Boorady joins TearScience from Carl Zeiss Meditec, where he was senior vice president of US sales, marketing, and customer service for all medical products.
Dr. Boorady will be replacing current CEO and co-founder Tim Willis.
“Boorady’s professional expertise and commercial track record make him the ideal candidate to lead TearScience to the next level,” Mr. Willis said in a company news release. “TearScience technology has already improved care for tens of thousands suffering from Meibomian Gland Dysfunction (MGD), with significant opportunity for ongoing education and treatment to help millions with the disease. Joe’s proven industry expertise will provide the energy to vastly expand use of the breakthrough LipiView II and LipiFlow devices.”
Dr. Boorady has more than 20 years in the industry as an eye care professional, educational leader, entrepreneur, and corporate executive after graduating in 1993 from the State University of New York (SUNY) College of Optometry with clinical honors. He has 13 years of clinical experience as the founder and owner of several primary eye care practices in New York and New Jersey, and 10 years with SUNY College of Optometry, where his last position was vice president clinical affairs and executive director overseeing 36 clinics throughout New York City. Dr. Boorady then spent 3 years as an equity partner and COO of an eye care software start-up. He also became an alumnus of the Harvard Business School, finally joining Carl Zeiss Meditec in 2009 where he led significant US growth at the ophthalmic technology giant.
“It is an honor to join TearScience, a company that has pioneered the most advanced technologies in Dry Eye and MGD,” Dr. Boorady said in the news release. “We thank Tim for all of his valuable contributions to the company, I hope to use my years of industry experience to complement the already impressive team that has brought innovation to the market and a commitment to helping eye care professionals diagnose and more effectively treat MGD."
The TearScience System, which includes LipiView II, the Korb Meibomian Gland Evaluator, and LipiFlow, allows eye care professionals to safely and effectively identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and vision clarity, causes ocular discomfort and is the root cause of most dry eye. LipiFlow has been clinically proven in multi-center, randomized, controlled clinical studies. Eye care practices that have implemented LipiView and LipiFlow report increased patient satisfaction, return on investment, and greater practice referrals.
TearScience provides extensive clinical training and support to assist with practice implementation.